{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:36Z","timestamp":1787755896268,"version":"build-2784847793"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:list list-type=\"plain\">\n                        <jats:list-item>\n                          <jats:p>\u00bb Intranasal salmon calcitonin (IN-CAL) is a well-tolerated, noninvasive antiresorptive agent with reproducible pharmacodynamic activity, despite lower systemic bioavailability than parenteral formulations.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\u00bb In preosteoporotic postmenopausal women, IN-CAL provides small, spine-limited preservation of bone mass, with minimal hip or forearm benefit; treatment response depends more on baseline bone turnover than on dose escalation.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\u00bb In established postmenopausal osteoporosis, IN-CAL produces early biochemical suppression (1-3 months) and small but consistent lumbar spine bone mineral density (BMD) gains with sustained therapy (\u22656-12 months).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\u00bb IN-CAL is less effective than bisphosphonates and modern anabolic agents for increasing BMD and reducing fracture risk; accordingly, its use is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\u00bb IN-CAL provides short-term pain relief for vertebral fractures in osteoporosis and offers a similarly time-limited analgesic benefit in acute orthopaedic settings, with pain reduction often within days and biochemical or skeletal effects evolving over subsequent weeks.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.rvw.26.00021","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:00:49Z","timestamp":1775584849000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management"],"prefix":"10.2106","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0181-6939","authenticated-orcid":false,"given":"Areeb","family":"Ahmad","sequence":"first","affiliation":[{"name":"Rothman Orthopaedics Florida at AdventHealth, Orlando, Florida"},{"name":"University of Central Florida College of Medicine, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-9818","authenticated-orcid":false,"given":"Kassem","family":"Ghayyad","sequence":"additional","affiliation":[{"name":"Rothman Orthopaedics Florida at AdventHealth, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-4835","authenticated-orcid":false,"given":"Elisabeth","family":"Davis","sequence":"additional","affiliation":[{"name":"Rothman Orthopaedics Florida at AdventHealth, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-4910","authenticated-orcid":false,"given":"Daniel","family":"Goltz","sequence":"additional","affiliation":[{"name":"Rothman Orthopaedics Florida at AdventHealth, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-5080","authenticated-orcid":false,"given":"G. Russell","family":"Huffman","sequence":"additional","affiliation":[{"name":"Rothman Orthopaedics Florida at AdventHealth, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2657-5123","authenticated-orcid":false,"given":"Olamide","family":"Oshikoya","sequence":"additional","affiliation":[{"name":"Rothman Orthopaedics Florida at AdventHealth, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4]]},"reference":[{"issue":"8574","key":"r1-20260407","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(87)92619-5","article-title":"1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin","volume":"2","author":"Reginster","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"r2-20260407","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.1989.tb00443.x","article-title":"Nasal calcitonin for treatment of established osteoporosis","volume":"30","author":"Overgaard","year":"1989","journal-title":"Clin Endocrinol"},{"issue":"2","key":"r3-20260407","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/8756-3282(95)00447-5","article-title":"Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis","volume":"18","author":"Thamsborg","year":"1996","journal-title":"Bone"},{"issue":"4","key":"r4-20260407","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"issue":"6853","key":"r5-20260407","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study","volume":"305","author":"Overgaard","year":"1992","journal-title":"BMJ"},{"issue":"4","key":"r6-20260407","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","article-title":"Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"17","author":"Adami","year":"1995","journal-title":"Bone"},{"issue":"5","key":"r7-20260407","first-page":"1783","article-title":"Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women","volume":"85","author":"Downs","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"r8-20260407","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"r9-20260407","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"r10-20260407","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1177\/1060028013509233","article-title":"Salmon calcitonin use and associated cancer risk","volume":"47","author":"Overman","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"11","key":"r11-20260407","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1210\/jc.2014-2239","article-title":"Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study","volume":"99","author":"Sun","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"r12-20260407","first-page":"205","article-title":"Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures","volume":"11","author":"Pun","year":"1989","journal-title":"Clin Ther"},{"key":"r13-20260407","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/17453674.1997.11744761","article-title":"Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study","volume":"275","author":"Lyritis","year":"1997","journal-title":"Acta Orthop Scand Suppl"},{"issue":"4","key":"r14-20260407","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF02508638","article-title":"The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment","volume":"58","author":"Kraenzlin","year":"1996","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"r15-20260407","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00296-005-0591-0","article-title":"Early effect of nasal salmon calcitonin on the bone marker crosslaps","volume":"26","author":"Ofluoglu","year":"2006","journal-title":"Rheumatol Int"},{"issue":"2","key":"r16-20260407","first-page":"186","article-title":"Analgesic effect of nasal salmon calcitonin during the early post-fracture period of the distal radius fracture","volume":"15","author":"Karponis","year":"2015","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"4","key":"r17-20260407","first-page":"e24.00045","article-title":"Safety and early results for off-label use of intranasal calcitonin for treatment of nondisplaced acromial and scapular spine stress fractures after reverse total shoulder arthroplasty","volume":"8","author":"Mandalia","year":"2024","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"issue":"5","key":"r18-20260407","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002512-199608050-00006","article-title":"Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis","volume":"8","author":"Plosker","year":"1996","journal-title":"Drugs Aging"},{"issue":"6","key":"r19-20260407","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00301940","article-title":"25 years of salmon calcitonin: from synthesis to therapeutic use","volume":"57","author":"Azria","year":"1995","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"r20-20260407","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1073\/pnas.64.2.771","article-title":"Amino acid sequence of salmon ultimobranchial calcitonin","volume":"64","author":"Niall","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"r21-20260407","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0169-6009(90)90011-4","article-title":"International Standards for salmon calcitonin, eel calcitonin, and the Asu1-7 analogue of eel calcitonin: calibration by international collaborative study","volume":"11","author":"Zanelli","year":"1990","journal-title":"Bone Miner"},{"issue":"10-11","key":"r22-20260407","first-page":"537","article-title":"Assessment of the biological activity of synthetic salmon calcitonin by intranasal administration in healthy volunteers","volume":"17","author":"Fiore","year":"1991","journal-title":"Drugs Exp Clin Res"},{"issue":"2","key":"r23-20260407","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/jcem-72-2-344","article-title":"Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women","volume":"72","author":"Overgaard","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"r24-20260407","first-page":"133","article-title":"Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects","volume":"2","author":"Reginster","year":"1987","journal-title":"Bone Miner"},{"issue":"2","key":"r25-20260407","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1172\/JCI112584","article-title":"Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization","volume":"78","author":"Nicholson","year":"1986","journal-title":"J Clin Invest"},{"issue":"1","key":"r26-20260407","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/path.1711360104","article-title":"Calcitonin alters behaviour of isolated osteoclasts","volume":"136","author":"Chambers","year":"1982","journal-title":"J Pathol"},{"issue":"4","key":"r27-20260407","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jcem-57-4-819","article-title":"The sensitivity of isolated osteoclasts to morphological transformation by calcitonin","volume":"57","author":"Chambers","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl","key":"r28-20260407","first-page":"333s","article-title":"Acute effects of calcitonin on osteoclasts in man","volume":"5","author":"Singer","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"r29-20260407","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/17453678308992912","article-title":"Early effects of parathormone and calcitonin on the number of osteoclasts and on serum-calcium in rats","volume":"54","author":"Hedlund","year":"1983","journal-title":"Acta Orthop Scand"},{"issue":"5","key":"r30-20260407","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00310194","article-title":"Effects of calcitonin on bone quality and osteoblastic function","volume":"52","author":"Wallach","year":"1993","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"r31-20260407","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endo-123-1-159","article-title":"The anti-bone-resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation","volume":"123","author":"Farley","year":"1988","journal-title":"Endocrinology"},{"issue":"3","key":"r32-20260407","doi-asserted-by":"crossref","first-page":"E627","DOI":"10.1152\/ajpendo.00307.2002","article-title":"Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity","volume":"284","author":"Villa","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"r33-20260407","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1172\/JCI110319","article-title":"Calcitonin stimulates bone formation when administered prior to initiation of osteogenesis","volume":"68","author":"Weiss","year":"1981","journal-title":"J Clin Invest"},{"key":"r34-20260407","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bonr.2018.04.006","article-title":"The reproducibility of measuring trabecular bone parameters using a commercially available high-resolution magnetic resonance imaging approach: a pilot study","volume":"8","author":"West","year":"2018","journal-title":"Bone Rep"},{"issue":"4","key":"r35-20260407","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0026-0495(84)90187-2","article-title":"Long-term calcitonin therapy in postmenopausal osteoporosis","volume":"33","author":"Gruber","year":"1984","journal-title":"Metabolism"},{"issue":"3","key":"r36-20260407","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02556055","article-title":"Effect of calcitonin and vitamin D in osteoporosis","volume":"45","author":"Palmieri","year":"1989","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"r37-20260407","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/09513599409023627","article-title":"The effect of intranasal salmon calcitonin on biochemical parameters of bone turnover in postmenopausal women","volume":"8","author":"Balint-Peri\u0107","year":"1994","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"r38-20260407","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000294874","article-title":"Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density","volume":"33","author":"Perrone","year":"1992","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"r39-20260407","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00297179","article-title":"Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study","volume":"55","author":"Overgaard","year":"1994","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"r40-20260407","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S8756-3282(96)00307-9","article-title":"Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover","volume":"20","author":"Schlemmer","year":"1997","journal-title":"Bone"},{"issue":"5","key":"r41-20260407","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s002239900448","article-title":"Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover","volume":"62","author":"Ongphiphadhanakul","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"r42-20260407","doi-asserted-by":"crossref","first-page":"1744806917720316","DOI":"10.1177\/1744806917720316","article-title":"Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression","volume":"13","author":"Ito","year":"2017","journal-title":"Mol Pain"},{"issue":"2","key":"r43-20260407","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/003693307802300211","article-title":"The therapeutic uses of calcitonin","volume":"23","author":"Martin","year":"1978","journal-title":"Scott Med J"},{"issue":"3-4","key":"r44-20260407","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02001904","article-title":"Calcitonin and its antinociceptive activity: animal and human investigations 1975-1992","volume":"41","author":"Braga","year":"1994","journal-title":"Agents Actions"},{"issue":"4","key":"r45-20260407","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00558497","article-title":"Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin","volume":"37","author":"Franceschini","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"16","key":"r46-20260407","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0024-3205(90)90526-W","article-title":"Salmon calcitonin given by nasal spray or by injection does not increase beta-endorphin levels in normal men","volume":"47","author":"Vescovi","year":"1990","journal-title":"Life Sci"},{"issue":"4","key":"r47-20260407","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv Transl Res"},{"issue":"11","key":"r48-20260407","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/pharmaceutics11110598","article-title":"Perivascular and perineural pathways involved in brain delivery and distribution of drugs after intranasal administration","volume":"11","author":"Lochhead","year":"2019","journal-title":"Pharmaceutics"},{"issue":"4","key":"r49-20260407","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J Pharm Sci"},{"issue":"2","key":"r50-20260407","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal drug delivery: recent developments and future prospects","volume":"161","author":"Illum","year":"2012","journal-title":"J Control Release"},{"issue":"1","key":"r51-20260407","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer? A review and meta-analysis","volume":"27","author":"Wells","year":"2016","journal-title":"Osteoporos Int"},{"issue":"1","key":"r52-20260407","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jbmr.5650090110","article-title":"Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin","volume":"9","author":"Reginster","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"8","key":"r53-20260407","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2362.1994.tb01108.x","article-title":"A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium","volume":"24","author":"Reginster","year":"1994","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"r54-20260407","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF00298742","article-title":"Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment","volume":"56","author":"Lyritis","year":"1995","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"r55-20260407","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s002239900076","article-title":"Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis","volume":"59","author":"Ellerington","year":"1996","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"r56-20260407","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/8756-3282(96)00084-1","article-title":"Salmon calcitonin in the prevention of bone loss at perimenopause","volume":"18","author":"Arnala","year":"1996","journal-title":"Bone"},{"issue":"6697","key":"r57-20260407","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.299.6697.477","article-title":"Effect of salcatonin given intranasally on early postmenopausal bone loss","volume":"299","author":"Overgaard","year":"1989","journal-title":"BMJ"},{"issue":"4","key":"r58-20260407","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/0149-2918(95)80044-1","article-title":"Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study","volume":"17","author":"Overgaard","year":"1995","journal-title":"Clin Ther"},{"issue":"4","key":"r59-20260407","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00301638","article-title":"An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss","volume":"50","author":"Gennari","year":"1992","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"r60-20260407","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0002-9343(99)80344-1","article-title":"A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss","volume":"98","author":"Reginster","year":"1995","journal-title":"Am J Med"},{"issue":"1","key":"r61-20260407","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00198-014-2937-5","article-title":"Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women","volume":"26","author":"Rizzoli","year":"2015","journal-title":"Osteoporos Int"},{"issue":"4","key":"r62-20260407","first-page":"387","article-title":"Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate [in Spanish]","volume":"128","author":"Campusano","year":"2000","journal-title":"Rev Med Chil"},{"issue":"1","key":"r63-20260407","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00310161","article-title":"Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers","volume":"55","author":"Nielsen","year":"1994","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"r64-20260407","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00586-005-0916-4","article-title":"The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis","volume":"15","author":"Papadokostakis","year":"2006","journal-title":"Eur Spine J"},{"issue":"1","key":"r65-20260407","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s002239900077","article-title":"A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin","volume":"59","author":"Overgaard","year":"1996","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"r66-20260407","first-page":"169","article-title":"Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis [in Italian]","volume":"14","author":"Agnusdei","year":"1989","journal-title":"Minerva Endocrinol"},{"issue":"1","key":"r67-20260407","first-page":"12","article-title":"Multicentric comparative study of synthetic salmon calcitonin nasally administered in the treatment of established postmenopausic osteoporosis","volume":"12","author":"Abellan Perez","year":"1995","journal-title":"An Med Interna"},{"issue":"121","key":"r68-20260407","first-page":"38","article-title":"Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis [in Russian]","author":"Kopaliani","year":"2005","journal-title":"Georgian Med News"},{"issue":"3","key":"r69-20260407","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10067-004-1004-6","article-title":"Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study","volume":"24","author":"Kaskani","year":"2005","journal-title":"Clin Rheumatol"},{"key":"r70-20260407","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/17453674.1997.11744760","article-title":"A double blind study of intranasal calcitonin for established postmenopausal osteoporosis","volume":"275","author":"Kapetanos","year":"1997","journal-title":"Acta Orthop Scandi Suppl"},{"issue":"3","key":"r71-20260407","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.maturitas.2004.07.013","article-title":"The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis","volume":"51","author":"Colpan","year":"2005","journal-title":"Maturitas"},{"issue":"5","key":"r72-20260407","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02556148","article-title":"Effect of different doses of nasal salmon calcitonin on bone mass","volume":"48","author":"Thamsborg","year":"1991","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"r73-20260407","first-page":"459","article-title":"Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study","volume":"6","author":"Pontiroli","year":"1994","journal-title":"Aging (Milano)"},{"issue":"suppl 1","key":"r74-20260407","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF01621909","article-title":"Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis","volume":"3","author":"Gennari","year":"1993","journal-title":"Osteoporos Int"},{"issue":"2","key":"r75-20260407","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00296-004-0549-7","article-title":"Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis","volume":"26","author":"Tekeo\u011flu","year":"2005","journal-title":"Rheumatol Int"},{"issue":"9","key":"r76-20260407","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/0003-4819-148-9-200805060-00003","article-title":"Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture","volume":"148","author":"Cadarette","year":"2008","journal-title":"Ann Intern Med"},{"issue":"suppl 3","key":"r77-20260407","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1007\/BF01623004","article-title":"Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin","volume":"3","author":"Adami","year":"1993","journal-title":"Osteoporos Int"},{"issue":"8","key":"r78-20260407","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-1241.2001.tb11111.x","article-title":"Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis","volume":"55","author":"Dursun","year":"2001","journal-title":"Int J Clin Pract"},{"issue":"1","key":"r79-20260407","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01623456","article-title":"Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis","volume":"7","author":"Flicker","year":"1997","journal-title":"Osteoporos Int"},{"issue":"11","key":"r80-20260407","first-page":"e98114","article-title":"Nandrolone decanoate for postmenopausal osteoporosis: a systematic review and meta-analysis of randomized trials","volume":"17","author":"Camara","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"r81-20260407","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0889-8529(02)00060-9","article-title":"Calcitonin","volume":"32","author":"Silverman","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"r82-20260407","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/17453679808999045","article-title":"Effect of nasal salmon calcitonin on post-traumatic osteopenia following ankle fracture. A randomized double-blind placebo-controlled study in 24 patients","volume":"69","author":"Petersen","year":"1998","journal-title":"Acta Orthop Scand"},{"issue":"4","key":"r83-20260407","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000085121","article-title":"Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty","volume":"51","author":"Peichl","year":"2005","journal-title":"Gerontology"},{"issue":"6","key":"r84-20260407","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00223-001-2111-x","article-title":"Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture","volume":"71","author":"Huusko","year":"2002","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"r85-20260407","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1302\/0301-620X.86B3.14300","article-title":"The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial","volume":"86","author":"Karachalios","year":"2004","journal-title":"J Bone Joint Surg Br"},{"issue":"6","key":"r86-20260407","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00590-016-1816-5","article-title":"Calcitonin effects on shoulder adhesive capsulitis","volume":"26","author":"Rouhani","year":"2016","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"12","key":"r87-20260407","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jcms.2021.08.002","article-title":"Evaluation of the efficacy of salmon calcitonin nasal spray on bone healing following open reduction and internal fixation of mandibular fractures: a randomized controlled trial","volume":"49","author":"Roy","year":"2021","journal-title":"J Craniomaxillofac Surg"}],"container-title":["JBJS Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.RVW.26.00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:54:42Z","timestamp":1787752482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.RVW.26.00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.rvw.26.00021","relation":{},"ISSN":["2329-9185"],"issn-type":[{"value":"2329-9185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}